News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Kashiv Biosciences Announces Positive Phase 1 Study Outcomes for ADL018, a Biosimilar Candidate for Xolair® (Omalizumab)
Wednesday, July 05, 2023Kashiv Biosciences LLC Kashiv or the Company has announced the successful completion of a Phase clinical study for ADL a biosimilar candidate to Xolair omalizumab in healthy volunteers
Journey Medical Corporation to Reveal Phase 3 Trial Findings for DFD-29 in Papulopustular Rosacea Treatment Around July 10, 2023
Tuesday, July 04, 2023Journey Medical Corporation Nasdaq DERM has made an announcement regarding the upcoming release of the topline results for its Phase clinical trials of DFD a potential treatment for moderate to severe papulopustular rosacea PPR
Infant Bacterial Therapeutics' New Product Receives FDA Orphan Drug Designation
Tuesday, July 04, 2023IBT has received orphan drug designation from the FDA for their product IBP which is intended for the treatment of gastroschisis Gastroschisis is a rare condition in infants that poses risks such as growth retardation sepsis and NEC often resulting i...
NLS Pharmaceutics Receives FDA Review and IRB Approval for Full Study Protocol, Advances Phase 3 Clinical Program (AMAZE) for Mazindol Er in the Treatment of Narcolepsy
Tuesday, July 04, 2023NLS Pharmaceutics Ltd Nasdaq NLSP has made significant announcements regarding the development of their drug Mazindol ER for narcolepsy type The US Food and Drug Administration FDA has thoroughly reviewed the NLS study protocol which is part of the...
Scisparc Granted Approval for Phase IIb Clinical Trial of Novel Treatment SCI-110 for Tourette Syndrome in Germany
Monday, July 03, 2023SciSparc Ltd Nasdaq SPRC a clinicalstage pharmaceutical company specializing in therapies for central nervous system disorders has received approval from the Federal Institute for Drugs and Medical Devices in Germany BfArM to conduct a Phase IIb clin...
Sandoz Enters US Immunology Market With Launch of Hyrimoz® (Adalimumab-adaz) High-concentration Formulation
Monday, July 03, 2023Sandoz a global leader in generic pharmaceuticals and biosimilars has announced the launch of the citratefree highconcentration formulation HCF of its biosimilar Hyrimoz adalimumabadaz injection in the United States starting July
Tonix Pharmaceuticals Successfully Acquires Two FDA-Approved Migraine Products Already in the Market
Monday, July 03, 2023Tonix Pharmaceuticals Holding Corp Nasdaq TNXP and its subsidiary Tonix Medicines Inc have recently completed the acquisition of two FDAapproved products from UpsherSmith Laboratories LLC
Zealand Pharma Reports Encouraging Findings From Phase 1 Trial of Multiple Ascending Dose With Amylin Analog ZP8396
Monday, July 03, 2023Zealand Pharma AS Nasdaq ZEAL CVRno a biotechnology company specializing in the development of innovative peptidebased medicines has announced the results of Part of a multiple ascending dose MAD trial for ZP This compound is a longacting amylin an...
Kissei Unveils Iktos AI Drug Discovery System
Monday, July 03, 2023Iktos a company specializing in Artificial Intelligence AI for new drug design has recently announced a collaboration with Kissei Pharmaceutical Co Ltd a prominent Japanese pharmaceutical company with a focus on urology kidneydialysis and unmet medic...
Sosei Heptares Administers First Dose in Phase I Trial Evaluating HTL0048149, a Novel GPR52 Agonist for Schizophrenia
Monday, July 03, 2023Sosei Group Corporation TSE has commenced a Phase I clinical trial for HTL HTL an innovative GPR agonist The drug is being developed for the treatment of schizophrenia and related neurological diseases
